Search
BRD-810
go.drugbank.com/drugs/DB23607ExperimentalBRD-810 is an experimental small molecule being investigated as a potential anti-cancer medication. It is an inhibitor of the protein myeloid cell leukemia 1 (MCL1). [A274263]
AEF0117
go.drugbank.com/drugs/DB27675InvestigationalAEF0117 is a small molecule drug. AEF0117 is under investigation in clinical trial NCT05554926 (Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects).
Synonyms: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one, 3β-(4-methoxybenzyloxy)pregn-5-en-20-oneMWN117
go.drugbank.com/drugs/DB33969ExperimentalMWN117 is a small molecule drug. MWN117 is under investigation in clinical trial NCT07824804 (Phase 1 Clinical Study of MWN117 Injection in Healthy Participants and Participants With Obesity).
Butyrylthiocholine
go.drugbank.com/drugs/DB04250ExperimentalA sulfur-containing analog of butyrylcholine which is hydrolyzed by butyrylcholinesterase to butyrate and thiocholine. It is used as a reagent in the determination of butyrylcholinesterase activity.
D-Treitol
go.drugbank.com/drugs/DB03278ExperimentalA four-carbon sugar that is found in algae, fungi, and lichens. It is twice as sweet as sucrose and can be used as a coronary vasodilator. [PubChem]
Synonyms: D-TreitolOrbifloxacin
go.drugbank.com/drugs/DB11443ExperimentalVet approvedOrbifloxacin is a fluoroquinolone antibiotic. It is marketed by Schering-Plough Animal Health and approved for certain infections in dogs.
Categories: 4-Quinolones, Cytochrome P-450 CYP1A2 InhibitorsRoyal jelly
go.drugbank.com/drugs/DB14250InvestigationalRoyal jelly is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: WOMEN`S MULTIVITE WITH EVENING PRIMROSE OIL,ROYAL JELLY & KOREAN GINSENG, Vitasen C 100 with Royal Jelly Chewable TabletProducts: KORDEL`S ROYAL JELLY 1000 MG CAPSULERosemary
go.drugbank.com/drugs/DB14272InvestigationalRosemary is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
DLO6002
go.drugbank.com/drugs/DB05179ExperimentalDLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
Gantacurium
go.drugbank.com/drugs/DB05710InvestigationalGantacurium chloride is a new, investigational, non-depolarizing ultra-short acting neuromuscular blocker. It is being developed by Avera Pharmaceuticals.
Categories: Heterocyclic Compounds, 2-Ring